Synthetic Biologics presents 2 posters at Digestive Disease Week

Synthetic Biologics, a company focused on microbiome research, presented two posters at Digestive Disease Week this year.

The posters are titled:

•    SYN-004, a Clinical Stage Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora fromAntibiotic-Mediated Damage in Humanized Pigs
•    Lovastatin Improves Stool Form in Methanobrevibacter smithii Colonized Rats with Constipation

The first poster summarizes preclinical data supporting the ability of SYN-004 to degrade certain beta-lactam antibiotics in the GI tract. The data supports SYN-004 as a therapy for the prevention of C. difficile infection and antibiotic-associated diarrhea.

"These findings support our ongoing Phase 2a clinical trial that is evaluating the ability of two different dose strengths of SYN-004 to degrade residual IV ceftriaxone in the GI tract of up to 20 healthy participants with functioning ileostomies, without affecting the concentrations of IV ceftriaxone in the bloodstream," said Jeffrey Riley, CEO of Synthetic Biologics. "We are on schedule to report topline data from the Phase 2a clinical trial of SYN-004 this quarter, with a Phase 2b clinical trial anticipated to initiate during the second half of this year."

The second poster summarizes preclinical data supporting the advance of the company's novel SYN-010.

"The presentation at the DDW meeting highlighted the therapeutic potential of SYN-010 for IBS-C," said Mr. Riley. "This research, along with the fact that SYN-010 is a new modified-release formulation of a widely prescribed statin drug, provides a strong body of evidence as Synthetic Biologics seeks to move our IBS-C program into a Phase 2 clinical trial during the second quarter of this year, with topline results anticipated to follow during the second half of this year."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast